Extensive muscle necrosis after long-term treatment with aminocaproic acid (EACA) in a case of hereditary periodic edema.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000614:Aminocaproates / Q000009:adverse effects*; D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001772:Blood Cell Count; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D001780:Blood Coagulation Tests; D001792:Blood Platelets; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000652:urine; D004285:Dogs; D005165:Factor V / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D000882:Haplorhini; D006461:Hemolysis; D006801:Humans; D006933:Hyperbilirubinemia, Hereditary; D008297:Male; D008777:Methyltestosterone / Q000627:therapeutic use; D009135:Muscular Diseases / Q000139:chemically induced* / Q000201:enzymology; D009212:Myoglobinuria; D009336:Necrosis; D009638:Norepinephrine / Q000378:metabolism; D010958:Plasminogen / Q000032:analysis; D051381:Rats; D013053:Spectrophotometry; D013923:Thromboembolism / Q000139:chemically induced; D013925:Thromboplastin / Q000032:analysis
D000614:Aminocaproates; D005165:Factor V; D005169:Factor VIII; D005340:Fibrinogen; D010958:Plasminogen; D013925:Thromboplastin; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase; D001663:Bilirubin; D008777:Methyltestosterone; D009638:Norepinephrine